Ticker > Company >

Rekvina Labs share price

Rekvina Laboratories Ltd.

BSE: 526075 SECTOR: Trading  638   0   0

15.27
+0.72 (4.95%)
BSE: 02 Feb 4:00 PM

Price Summary

Today's High

₹ 15.27

Today's Low

₹ 15.27

52 Week High

₹ 15.27

52 Week Low

₹ 6.75

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

9.2 Cr.

Enterprise Value

9.43 Cr.

No. of Shares

0.6 Cr.

P/E

0

P/B

0

Face Value

₹ 5

Div. Yield

0 %

Book Value (TTM)

₹  -0.67

CASH

0.03 Cr.

DEBT

0.25 Cr.

Promoter Holding

41.3 %

EPS (TTM)

₹  -0.23

Sales Growth

0%

ROE

0 %

ROCE

0%

Profit Growth

-735.98 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 YearNA
5 YearNA

Profit Growth

1 Year-735.98%
3 Year-36.02%
5 Year-324.58%

ROE%

1 Year0%
3 Year-0.11%
5 Year-39.91%

ROCE %

1 Year0%
3 Year-0.03%
5 Year-35.47%

Debt/Equity

-0.7432

Price to Cash Flow

-47.97

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2025 41.30 0.00
Sep 2025 41.30 0.00
Jun 2025 41.30 0.00
Mar 2025 41.30 0.00
Dec 2024 41.30 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • The company has shown a poor profit growth of -36.0166960888551% for the Past 3 years.
  • Company has a poor ROE of -0.1114% over the past 3 years.
  • Company has a poor ROCE of -0.032% over the past 3 years
  • Company has negative cash flow from operations of -0.1919.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company has negative book value.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 0 0 0 0 0.2
Total Expenditure 0.07 0.02 0.04 0.04 0.23
Operating Profit -0.07 -0.02 -0.04 -0.04 -0.04
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.07 -0.02 -0.04 -0.04 -0.04
Tax 0 0 0 0 0
Profit After Tax -0.07 -0.02 -0.04 -0.04 -0.04
Adjusted EPS (Rs) -0.11 -0.04 -0.07 -0.06 -0.06

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 0 0 0 0 0
Total Expenditure 0.06 0.07 0 0.02 0.14
Operating Profit -0.06 -0.07 0 -0.02 -0.14
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.06 -0.07 0 -0.02 -0.14
Tax 0 0.01 0 0 0
Net Profit -0.06 -0.08 0 -0.02 -0.14
Adjusted EPS (Rs.) -0.11 -0.13 0 -0.03 -0.23

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 3.01 3.01 3.01 3.01 3.01
Total Reserves -2.92 -3 -3 -3.21 -3.35
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 0.15 0.18 0.19 0.2 0.36
Total Liabilities 0.24 0.19 0.2 0.01 0.03
Assets
Net Block 0.15 0.15 0.15 0 0
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.05 0.05 0.05 0 0
Loans & Advances 0.04 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 0.01 0 0.01 0.01 0.03
Total Assets 0.24 0.19 0.2 0.01 0.03
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -0.06 -0.08 0 -0.02 -0.14
Adjustment 0 0 0 0 0
Changes in Assets & Liabilities 0.06 0.04 0.01 0.01 -0.05
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.01 -0.04 0.01 -0.01 -0.19
Investing Cash Flow 0 0.04 0 0 0
Financing Cash Flow 0 0 0 0.01 0.21
Net Cash Flow -0.01 0 0.01 0 0.02

Corporate Actions

Investors Details

PARTICULARS Dec 2024% Mar 2025% Jun 2025% Sep 2025% Dec 2025%
promoters 41.30 41.30 41.30 41.30 41.30
amit mukesh shah 13.73 13.73 13.73 13.73 13.73
mukesh jamnadas shah 12.34 12.34 12.34 12.34 12.34
surbhit mukesh shah 15.22 15.22 15.22 15.22 15.22
PARTICULARS Dec 2024% Mar 2025% Jun 2025% Sep 2025% Dec 2025%
investors 58.70 58.70 58.70 58.70 58.70
abhijit dharmeshbhai meht... - 4.46 4.46 4.46 4.46
amitkumar arunkumar rao 1.65 1.65 1.65 1.65 1.65
amitkumar arunkumar rao h... - - - 4.72 4.72
arunkumar narsingh rao 3.93 3.93 3.93 3.93 3.93
dilsan pharma impex priva... - 6.40 6.40 6.40 6.40
khushali nemish badani 2.39 2.39 2.39 2.39 2.39
kishorbhai j suratwala 3.81 3.81 3.81 3.81 3.81
nemishbhai jayeshbhai bad... 1.50 1.50 1.50 1.50 1.50
niravbhai jashubhai patel... - 4.59 6.47 6.47 6.47
pareshkumar rameshchandra... 1.45 1.45 1.45 1.45 1.45
sanjay bhanubhai shah 1.08 1.08 1.08 1.08 1.08
amitkumar arunkumar rao- ... - - 4.72 - -
amitkumar arunkumar rao h... 4.72 4.72 - - -
ashamakam mercantile priv... 1.88 1.88 - - -
allergan trading services... 2.90 - - - -
divya jaswantkumar advani... 1.16 - - - -
jayaben jaswantbhai advan... 2.42 - - - -
neetu jain 3.50 - - - -
shilpa pramodbhai maniar 4.59 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Rekvina Labs Stock Price Analysis and Quick Research Report. Is Rekvina Labs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Rekvina Labs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Rekvina Labs has a PE ratio of -67.1799384073911 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Rekvina Labs has ROA of -652.8571% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Rekvina Labs has a Current ratio of 0.0891.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Rekvina Labs has a ROE of 0%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Rekvina Labs has a Debt to Equity ratio of -0.7432 which means that the company has low proportion of debt in its capital.

  • Sales growth: Rekvina Labs has reported revenue growth of 0% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Rekvina Labs for the current financial year is 0%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Rekvina Labs is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Rekvina Labs is Rs -0.2273. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Rekvina Labs in Ticker for free. Also, one can get the intrinsic value of Rekvina Labs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Rekvina Labs FAQs

Q1. What is Rekvina Labs share price today?
Ans: The current share price of Rekvina Labs is Rs 15.27.

Q2. What is the market capitalisation of Rekvina Labs?
Ans: Rekvina Labs has a market capitalisation of Rs 9.204756 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Rekvina Labs?
Ans: The PE ratio of Rekvina Labs is -67.1799384073911 and the P/B ratio of Rekvina Labs is -22.886690647482, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Rekvina Labs share?
Ans: The 52-week high share price of Rekvina Labs is Rs 15.27, and the 52-week low share price of Rekvina Labs is Rs 6.75.

Q5. Does Rekvina Labs pay dividends?
Ans: Currently, Rekvina Labs does not pay dividends. Dividend yield of Rekvina Labs is around 0%.

Q6. What are the face value and book value of Rekvina Labs shares?
Ans: The face value of Rekvina Labs shares is Rs 5, while the book value per share of Rekvina Labs is around Rs -0.6672. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Rekvina Labs?
Ans: Rekvina Labs has a total debt of Rs 0.2469 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Rekvina Labs?
Ans: The ROE of Rekvina Labs is 0% and ROCE of Rekvina Labs is 0%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Rekvina Labs a good buy for the long term?
Ans: The Rekvina Labs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Rekvina Labs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Rekvina Labs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Rekvina Labs’s financials?
Ans: You can review Rekvina Labs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Rekvina Labs
X